Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 331 | 特発性多中心性キャッスルマン病 | 1 |
331. 特発性多中心性キャッスルマン病
臨床試験数 : 33 / 薬物数 : 41 - (DrugBank : 21) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05345522 (ClinicalTrials.gov) | April 18, 2022 | 19/4/2022 | A Study of Anti-IL-6R mAb Injection in Patients With iMCD | A Single-arm, Open-label, Multi-center Phase ?a Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-IL-6R mAb Injection in the Treatment of Patients With Idiopathic Multicentric Castleman's Disease | Idiopathic Multicentric Castleman's Disease | Biological: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg;Biological: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg;Biological: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg | Beijing VDJBio Co., LTD. | NULL | Recruiting | 18 Years | N/A | All | 9 | Phase 2 | China |